Arcellx

Arcellx DSCR

Delisted

The Debt Service Coverage Ratio (DSCR) of Arcellx (ACLX) as of Nov 20, 2026 is -27.74. In the previous year, Debt Service Coverage Ratio (DSCR) was -362.90 — a change of -92.36% (higher).

DSCR

-27.74

YoY

-92.36%

Last updated:

Debt Service Coverage Ratio (DSCR) of Arcellx is 2025 -27.74 . Debt Service Coverage Ratio (DSCR) of Arcellx was 2024 -362.90 . It decreases by -92.36% higher compared to the previous year.

The Arcellx DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2022
-1.84 USD
Jan 1, 2023
5.28 USD
Jan 1, 2024
-362.90 USD
Jan 1, 2025
-27.74 USD
The Arcellx DSCR history
YEARDSCRYoY
-27.74-92.36%
-362.90-6,967.85%
5.28-386.81%
-1.84—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Debt Service Coverage Ratio (DSCR) of Arcellx is -27.74 in 2025.

Debt Service Coverage Ratio (DSCR) of Arcellx changed from -362.90 to -27.74, representing a -92.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Arcellx since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Arcellx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Arcellx

All Key Metrics — Arcellx